Category: Products

Felixvet Expands Xylitol-Free Meloxicam Portfolio for Dogs

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — June 25, 2026 — Felixvet Inc. today announced expanded availability of its FDA-approved Meloxicam Oral Suspension, a prescription non-steroidal anti-inflammatory drug (NSAID) indicated for the control of pain and inflammation associated with osteoarthritis in dogs. Featuring a 100% xylitol-free formulation, Meloxicam Oral Suspension provides veterinarians and pet owners with a trusted treatment option designed specifically for canine patients.

Product Details 

Two Felix Meloxicam Oral Suspension box sizes (100 mL and 32 mL) for dogs, featuring blue and white branding.

Felixvet Meloxicam Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

“Managing osteoarthritis is an important part of helping dogs maintain comfort, mobility, and quality of life,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “We’re proud to offer a 100% xylitol-free Meloxicam Oral Suspension that provides veterinarians and pet owners with a trusted FDA-approved treatment option while expanding availability across multiple package sizes to meet the needs of practices and patients.”

Osteoarthritis is one of the most common chronic conditions affecting dogs and can significantly impact mobility, activity levels, and overall comfort. Meloxicam Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis and is formulated for convenient oral administration.

Meloxicam Oral Suspension contains 1.5 mg of meloxicam per milliliter and is available in the following bottle sizes:

  • 10 mL
  • 32 mL
  • 100 mL
  • 200 mL

The oral suspension should be shaken well before use and administered according to veterinary dosing instructions. The included dosing system helps support accurate measurement, particularly in small dogs.

“Veterinarians and pet owners value products that combine safety, convenience, and flexibility,” added Lauren Landolph. “The addition of multiple bottle sizes and a 100% xylitol-free formulation reflects our commitment to developing practical solutions that support the everyday management of chronic conditions such as osteoarthritis.”

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and pet owners with high-quality treatment options across a broad range of therapeutic categories. The original approval of Meloxicam Oral Suspension was announced in December 2025 and remains an important component of Felixvet’s growing pain management portfolio.

For additional information, please contact info@felixvet.com  

About Felixvet
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners. 

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com

FDA Authorizes Felixvet to Treat New World Screwworm in Pets 

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — June 13, 2026 — Felixvet Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) for Nitenpyram Tablets (nitenpyram) for the treatment of infestations caused by New World Screwworm (Cochliomyia hominivorax) larvae, also known as myiasis, in dogs, puppies, cats and kittens weighing at least two pounds and four weeks of age or older. 

According to the FDA, Nitenpyram Tablets are the first generic animal drug authorized for use against New World Screwworm, marking an important milestone in the ongoing effort to combat one of the most destructive animal parasites in the Western Hemisphere. The authorization comes as federal and state officials respond to the first confirmed domestic cases of New World Screwworm in the United States in more than six decades. 

Product Details 

Three orange and white boxes and two blister packets of Nitenpyram tablets (New World Screwworm treatment) from Felixvet.

Felixvet Nitenpyram Tablets are authorized under FDA Emergency Use Authorization (EUA 006661) for the treatment of New World Screwworm infestations in eligible dogs and cats.

“We’re incredibly proud to receive FDA Emergency Use Authorization for the first generic animal drug authorized to treat New World Screwworm in dogs and cats,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels,  Felixvet. “This authorization represents a significant milestone not only for Felixvet, but for animal health preparedness in the United States. As concerns surrounding New World Screwworm continue to grow, expanding access to effective treatment options for veterinarians and pet owners becomes increasingly important.”

New World Screwworm is a parasitic fly whose larvae infest living tissue, creating painful and potentially life-threatening wounds in animals. Unlike most fly larvae that feed on dead tissue, New World Screwworm larvae consume living flesh and can cause severe tissue damage if left untreated. The parasite poses a significant threat to livestock, pets, wildlife, and in rare cases, humans. 

The FDA concluded that, based on the totality of available scientific evidence, it is reasonable to believe that Nitenpyram Tablets may be effective for the treatment of New World Screwworm infestations in dogs and cats under the conditions outlined in the Emergency Use Authorization. The agency further determined that the known and potential benefits of the product outweigh its known and potential risks. 

Nitenpyram acts rapidly and is expected to kill most New World Screwworm larvae within hours of administration. The product is available over the counter and is supplied in two strengths: 

  • 11.4 mg tablets 
  • 57 mg tablets 

Dosage is based on body weight and is authorized for dogs, puppies, cats and kittens weighing at least two pounds and four weeks of age or older. Veterinarians may still recommend wound management, removal of remaining larvae, and additional follow-up care depending on the severity of the infestation. 

“Generic animal health products play an important role in ensuring access, availability, and preparedness,” added Lauren Landolph. “We’re honored that Nitenpyram Tablets can serve as an additional tool in the fight against New World Screwworm and help support veterinarians, pet owners, and animal health professionals working to protect companion animals.” 

The authorization follows broader federal efforts to monitor, contain, and prevent the spread of New World Screwworm across North America. Felixvet remains committed to supporting animal health through the development and commercialization of high-quality pharmaceutical products that address evolving veterinary needs. 

For additional information, please contact info@felixvet.com  

About Felixvet
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners. 

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com

Felixvet Receives FDA Approval for Cefpodoxime Proxetil Tablets

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — October 30, 2025 — Felixvet is dedicated to advancing veterinary care and addressing the needs of veterinarians, pet owners and distributors. To further this commitment, Felixvet is now introducing Cefpodoxime Proxetil tablets, an antimicrobial indicated for the treatment of skin infections in dogs. Felixvet, Inc., a manufacturer based in Ireland of generic pharmaceuticals for companion animals,  established its North American headquarters in Kansas City, Missouri, in 2023.

“Felixvet is committed to providing affordable options without sacrificing quality or reliability,” said Vince Palasota, President of North America at Felixvet. “We adhere to rigorous FDA standards, ensuring safety and efficacy in every product.”

Cefpodoxime Proxetil is a broad-spectrum antibiotic, effective against a wide variety of bacteria. It is primarily prescribed for the treatment of skin infections in dogs, such as those caused by Staphylococcus and Streptococcus bacteria. It works by interfering with the production of bacterial cell walls, ultimately killing vulnerable bacteria. Cefpodoxime Proxetil is a third-generation cephalosporin, meaning it has a wider range of efficacy as compared to previous generations. 

Cefpodoxime Proxetil is easy to administer, with its single daily dosing. It is available in 100 mg and 200 mg tablets and is intended for oral use in dogs only. 

Felixvet established its North American headquarters in Kansas City, Missouri, in 2023. Felixvet currently holds 20 FDA approvals, with multiple additional products in development and launches planned across a broad range of therapeutic categories.

For more information, contact info@felixvetus.com.

About Felixvet:
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player, focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com

Felixvet Receives FDA Approval for Clindamycin Hydrochloride Tablets

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — September 22, 2025 — Felixvet Inc. is proud to announce a recent FDA approval for Clindamycin Hydrochloride Tablets, an oral antibiotic approved for use in dogs to treat skin infections, abscesses, dental infections and osteomyelitis caused by susceptible bacterial strains.

“With the approval of Clindamycin Hydrochloride Tablets, we’re expanding access to a trusted treatment option that veterinarians rely on for managing common yet potentially serious infections,” said Vince Palasota, President of North America at Felixvet. “This product reflects our ongoing commitment to quality, affordability and clinical relevance.”

Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis and has demonstrated activity against a broad spectrum of aerobic and anaerobic bacteria, including Staphylococcus aureus, Staphylococcus intermedius, Bacteroides fragilis and Clostridium perfringens. It is especially effective for deep-seated infections, such as those in bone or dental tissues.

The tablets are available in 25 mg, 75 mg and 150 mg strengths and are dosed every 12 hours, with duration of treatment varying based on infection type, typically a few days for acute infections and up to 28 days for osteomyelitis.

“Clindamycin is a proven, versatile therapeutic, and we’re proud to add it to our growing portfolio,” added Palasota. “We look forward to continuing to deliver solutions that meet the daily needs of veterinarians and their patients.”

Felixvet established its North American headquarters in Kansas City, Missouri, in 2023. Felixvet currently holds 20 FDA approvals, with multiple additional products in development and launches planned across a broad range of therapeutic categories.

For more information, contact info@felixvetus.com.

About Felixvet:
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player, focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com

Felixvet Receives FDA Approval for Methimazole Coated Tablets

Posted on by developer@wearewoodruff.com

Kansas City, MO — September 19, 2025 — Felixvet Inc. has received the first FDA generic approval for Methimazole Coated Tablets, an antithyroid drug indicated for the treatment of hyperthyroidism in cats. With this milestone, Felixvet continues to advance its mission of offering high-quality, affordable medications for companion animals. The company established its North American headquarters in Kansas City, Missouri, in 2023 and aims to serve veterinarians, pet owners and distributors alike.

The U.S. Food and Drug Administration approved Methimazole Coated Tablets (ANADA 200-814) after determining the product is bioequivalent to the pioneer drug, Felimazole (NADA 141-292), originally approved in 2009. The approval followed a rigorous review of the drug’s safety and manufacturing quality.

“Felixvet is committed to meeting the clinical needs of veterinarians while offering affordable, reliable alternatives,” said Vince Palasota, President of North America at Felixvet. “Each of our products is developed to the highest regulatory standards to ensure consistency, quality and therapeutic equivalence.”

Hyperthyroidism is most commonly diagnosed in senior felines and results from an overproduction of thyroid hormones that may cause symptoms such as weight loss, increased thirst and urination, vomiting and hyperactivity. Methimazole Coated Tablets help manage this disease by inhibiting the synthesis of thyroid hormones.

Methimazole Coated Tablets are film-coated, which can aid in administration, and are supplied in 2.5 mg and 5 mg strengths for oral use. They are administered every 12 hours with dosage adjustments made in 2.5 mg increments, based on a cat’s response and veterinary guidance.

“Methimazole is an important therapy for managing feline hyperthyroidism, and we’re proud to add it to our growing portfolio,” added Palasota. “We look forward to continuing to deliver solutions that meet the daily needs of veterinarians and their patients.”

Felixvet established its North American headquarters in Kansas City, Missouri, in 2023. Felixvet currently holds 20 FDA approvals, with multiple additional products in development and launches planned across a broad range of therapeutic categories.

For more information, email info@felixvetus.com.

About Felixvet: 
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player, focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com

Felixvet Launches Carprofen Soft Chewable Tablets

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — April 2, 2025 — As part of its commitment to enhance animal health, Felixvet has successfully launched Carprofen Soft Chewable Tablets, now available through animal health distributors. Felixvet, Inc., a generic companion animal pharmaceutical manufacturer based in Ireland, established its North American headquarters in Kansas City, Missouri, in 2023.

“We are excited to announce the launch of our fifth carprofen product offering in the U.S. market,” said Vince Palasota, President of North America at Felixvet. “This development marks a significant step forward in providing quality, affordable healthcare solutions for pets without sacrificing efficacy, safety or reliability.”

Felixvet is leading the animal health market by introducing Carprofen Soft Chewable Tablets to its portfolio of carprofen products. This addition offers veterinarians five different forms of carprofen, each specifically designed to meet the diverse needs of their customers. 

“We are committed to introducing additional products that will help us become one of the leading companion animal generic drug companies globally,” states Palasota.

Carprofen Soft Chewable Tablets provide the same therapeutic benefits as other branded carprofen medications, but the new beef flavored Felixvet Soft Carprofen Chewable Tablets offer a state of the art, unique soft chewable tablet compared to the hard chewable tablet pioneer, RIMADYL®. They are easy to administer orally due to the palatable beef flavor. Felixvet’s Soft Chewable technology is based on traditional compression technology without the constraints imposed by current production processes such as extrusion or molding.

A nonsteroidal anti-inflammatory, Carprofen Soft Chewable Tablets relieve pain and inflammation associated with osteoarthritis. The tablets are therapeutically equivalent to the pioneer drug, RIMADYL®, with the same safety and efficacy. Available in three strengths, 25, 75 and 100 mg, each tablet is scored for easy and accurate dosing.

For more information, visit Felixvet.com or info@felixvetus.com.

About Felixvet: 
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com